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Abstract Ð The asymmetric lithiation-trapping of six-membered N-Boc 
heterocycles using s-BuLi and two different Alexakis diamines is reported. These 
readily available ligands outperform the current Ôbest-in-classÕ sparteine-type 
diamines in the lithiation and benzophenone trapping of N-Boc piperazines and the 
lithiation-cyclisation-trapping of N-Boc-4-chloro piperidine. In situ IR 
spectroscopy has been used to optimise lithiation times and to discover previously 
unknown subtleties regarding the lithiation step.  
The enantioselective α-functionalisation of N-Boc activated nitrogen heterocycles via lithiation-trapping 
methodology has become a mainstay of asymmetric heterocycle synthesis1 since its inception by Beak in 
1991.2 The alkaloid (Ð)-sparteine and the (+)-sparteine surrogate 1, developed in our laboratory,3 have 
become the most useful ligands for such s-BuLi-mediated transformations (Scheme 1). Whilst (Ð)-sparteine 
and its antipode are naturally occurring,4 the commercial availability has varied dramatically over the past 
20 years.5 Additionally, (+)-sparteine surrogate 1, although commercially available, is prohibitively 
expensive and is more commonly synthesised from (Ð)-cytisine.6 Recent developments from ourselves and 
Maulide have addressed the supply issues relating to these important diamines,7 but since 1 is only a pseudo-
enantiomer of (Ð)-sparteine, it exhibits significant differences in rates of organolithium-mediated 
transformations and it can also have different enantioselectivities.8 Given that the use of enantiomeric 
ligands is preferred in asymmetric synthesis, and the supply of sparteine is unreliable, we chose to revisit 
chiral diamines that are readily available as both enantiomers. In this regard, the C2-symmetric diamine 2,
9 
and pseudoephedrine-derived diamine 3,10 devised by Alexakis, seemed highly suitable and both can be 
easily synthesised in multi-gram quantities from readily available enantiopure precursors.11a   
 
Scheme 1. Structure of diamine ligands and an overview of the lithiation-trapping of N-Boc heterocycles 
 
Although diamines 2 and 3 were originally developed for the addition of MeLi to aromatic imines, both 
enantiomers of 2 have been used successfully in the lithiation-trapping of N-Boc pyrrolidine 4,11 giving 
comparable results to (Ð)-sparteine and the (+)-sparteine surrogate 1 (Scheme 1). Additionally, diamine 2 
has found some utility in the asymmetric lithiation-trapping of other N-containing heterocyles,12 aryl 
bromides13 and paracyclophanes14 as well as the dynamic resolution of lithiated N-thiopivaloyl azetidine.15  
Since diamine 2 can be considered the diamine of choice for the lithiation of N-Boc pyrrolidine 4, we 
decided to investigate the use of diamine (S,S)-2, and the structurally related diamine (R,R)-3, in the 
asymmetric lithiation-trapping of six-membered N-Boc piperazines 516 and N-Boc-4-phenyl piperidine 6 
(Scheme 1).12a As part of this study, we also included the lithiation-cyclisation-trapping of N-Boc-4-chloro 
piperidine 7. Lithiation of 7 is followed by internal substitution of the chloride to give a cyclopropane which 
then undergoes regioselective lithiation via removal of the more acidic α-N-Boc cyclopropyl proton.12d,17 
Herein, we present our results. 
First, the asymmetric lithiation-trapping of N-Boc-NÕ-benzyl piperazine 8 using s-BuLi and diamine (S,S)-
2 was explored. In order to determine the time required for lithiation of N-Boc piperazine 8, in situ IR 
spectroscopy, which has become a popular technique in this context,8b,16a,18 was employed. A solution of N-
Boc piperazine 8 (1.0 mmol) in Et2O (14 mL) at −78 ¡C (in the presence of diamine (S,S)-2) exhibited a 
νC=O peak at 1700 cm
−1. On addition of s-BuLi, lithiation proceeded to give the organolithium 10 (νC=O peak 
at 1646 cm−1); formation of a pre-lithiation complex 9, assigned to a peak at 1680 cm−1, was also observed 
throughout the lithiation (Scheme 2, 2-D plot of absorbance versus time). As the reaction progressed, the 
proportion of both N-Boc piperazine 8 and pre-lithiation complex 9 decreased whereas that of the lithiated 
species 10 steadily increased, with lithiation taking !30 min. For comparison, using s-BuLi and (Ð)-
sparteine or the (+)-sparteine surrogate 1, the lithiation time for N-Boc piperazine 8 is !60 min and !2 min 
respectively.16a Thus, s-BuLi/diamine (S,S)-2 shows intermediate reactivity compared to s-BuLi/(Ð)-
sparteine and s-BuLi/(+)-sparteine surrogate 1.  
 
Scheme 2. In situ IR spectroscopic monitoring of the asymmetric lithiation of N-Boc piperazine 8 with s-
BuLi/diamine (S,S)-2 
 
With an idea of the lithiation time established, we treated N-Boc-NÕ-benzyl piperazine 8 with s-BuLi and 
(S,S)-2 (Et2O, Ð78 ¡C, 1 h) followed by trapping with benzophenone. This gave adduct (S)-11 (in an 87:13 
ratio with alkene by-product 12), which was isolated in 60% yield and 86:14 er (Scheme 3). Alkene by-
product 12 is believed to have formed through a single electron transfer (SET) mechanism;19 one electron 
oxidation of lithiated N-Boc piperazine 8 by Ph2CO would give an α-amino radical which could lose a β-
hydrogen atom to give 12. In comparison with lithiation employing either (Ð)-sparteine or the (+)-sparteine 
surrogate 1,16a the reaction mediated by s-BuLi/diamine (S,S)-2 gives higher yields and enantiomeric ratios 
and a lower proportion of alkene 12, due to a decrease in SET side-reactions. With (Ð)-sparteine, (R)-11 
was isolated in 54% yield and 89:11 er; with (+)-sparteine surrogate 1, the yield and er of (S)-11 were 36% 
and 75:25 respectively. Employment of enantiomeric diamine (R,R)-2 would allow an efficient synthesis 
of (R)-11, an advanced intermediate in the synthesis of SHA-68, a neuropeptide S receptor antagonist.20  
 Scheme 3. Lithiation-trapping of N-Boc piperazine 8. *ratio determined by 1H NMR spectroscopy of the 
crude product.  
 
Next, we explored the lithiation-trapping of N-Boc-NÕ-methyl piperazine 13 using s-BuLi and diamines 
(S,S)-2 and (R,R)-3. Initial in situ IR spectroscopic studies showed that a solution of piperazine 13 and 
diamine (S,S)-2 in Et2O at Ð78 ¡C exhibited a νC=O peak at 1703 cm
−1 (Scheme 4A). Treatment with s-BuLi 
gave organolithium 15 (νC=O peak at 1646 cm
−1) via pre-lithiation complex 14 (νC=O peak at 1680 cm
−1). 
Interestingly, although lithiation of 13 initially proceeded rapidly, the reaction stalled at approximately 50% 
conversion within 8 min. This could account for the poor yield in the s-BuLi/diamine (S,S)-2-mediated 
lithiation-trapping of 13 (vide infra). Conversely, analogous in situ IR spectroscopic analysis of the 
lithiation of N-Boc-NÕ-methyl piperazine 13 with s-BuLi/diamine (R,R)-3 showed rapid and full conversion 
of 13 (νC=O peak at 1702 cm
−1) to the lithiated intermediate 15 (νC=O peak at 1646 cm
−1) via pre-lithiation 
complex 14 (νC=O peak at 1680 cm
−1). Lithiation was complete within 30 min.21  
  
Scheme 4. Panel A: In situ IR spectroscopic monitoring of the asymmetric lithiation of N-Boc piperazine 
13; Panel B: Lithiation-trapping of N-Boc piperazine 13. *ratio determined by 1H NMR spectroscopy of 
the crude product.  
 
Next, lithiation of N-Boc-NÕ-methyl piperazine 13 followed by trapping with benzophenone was 
investigated (Scheme 4B). In the presence of diamine (S,S)-2, oxazolidinone (S)-16 was obtained in 48% 
yield and 92:8 er. Interestingly, only a trace of alkene side-product 17 was observed. It is thought that the 
modest yield is due to only partial lithiation of N-Boc piperazine 13 as indicated by in situ IR spectroscopy. 
Lithiation-trapping in the presence of s-BuLi and pseudoephedrine-derived diamine (R,R)-3 resulted in 
oxazolidinone (R)-16 being isolated in 55% yield and 92:8 er, without the formation of any alkene side-
product 17. In comparison, the more commonly employed diamines for lithiation-trapping of N-Boc 
heterocycles, (Ð)-sparteine and the (+)-sparteine surrogate 1, performed worse in terms of yield and 
enantioselectivity. With (Ð)-sparteine, oxazolidinone (R)-16 was isolated in 45% yield and 88:12 er; with 
(+)-sparteine surrogate 1, the yield and er of (S)-16 were 36% and 85:15 er respectively. This is believed 
to be due to an increase in SET side-reactions. Although it is currently unknown how the Alexakis diamines 
2 and 3 suppress SET processes, they appear well-suited for use in the lithiation-trapping of N-Boc 
piperazines with benzophenone. 
We then addressed the lithiation of N-Boc-NÕ-tert-butyl piperazine 18. Previous in situ IR spectroscopic 
studies16a had shown that lithiation of N-Boc piperazine 18 with s-BuLi and (Ð)-sparteine in Et2O at Ð78 ¡C 
took over 5 h to reach completion, which is significantly slower than either N-Boc-NÕ-benzyl piperazine 8 
(~60 min)16a or N-Boc-NÕ-methyl piperazine 13 (~90 min) (for full details see SI). With (+)-sparteine 
surrogate 1, the same trend was observed: lithiation of N-Boc-NÕ-tert-butyl piperazine 18 took longer (5 
min) than either N-Boc-NÕ-benzyl piperazine 8 (2 min) or N-Boc-NÕ-methyl piperazine 13 (2 min). We 
were interested to see if this trend continued with the structurally distinct Alexakis diamines. As with N-
Boc-NÕ-methyl piperazine 13, lithiation of 18 with s-BuLi and diamine (S,S)-2 resulted in rapid but 
incomplete lithiation (see SI for full details). However, using s-BuLi and diamine (R,R)-3, complete 
lithiation occurred within 30 min, which is in fact a similar rate of lithiation as that observed with N-Boc-
NÕ-methyl piperazine 13 (c.f. 30 min, Scheme 4A). Interestingly, the sparteine-class ligands appear to result 
in more varied rates of lithiation of N-Boc piperazines than the Alexakis ligands, possibly due to the greater 
rigidity of the bispidine core.  
Lithiation of N-Boc-NÕ-tert-butyl piperazine 18 using diamine (S,S)-2 under standard conditions (s-BuLi, 
Et2O, Ð78 ¡C, 1 h) and trapping with benzophenone gave adduct (S)-19 in 36% yield and 85:15 er, without 
the formation of an alkene side-product (Scheme 5). Similarly, trapping with methyl chloroformate gave 
ester (S)-20 in 34% yield and 88:12 er as the sole product. Here, the modest yields are likely to be caused 
by partial lithiation, as observed by in situ IR spectroscopy. Conversely, lithiation of 18 with s-
BuLi/diamine (R,R)-3 and trapping with methyl chloroformate gave ester (R)-20 in a good 69% yield and 
81:19 er. 
 Scheme 5. Lithiation-trapping of N-Boc-NÕ-tert-butyl piperazine 18  
 
Next, we turned our attention to the lithiation-trapping of N-Boc-4-phenyl piperidine 6 using diamines 
(S,S)- and (R,R)-2. Treatment of N-Boc-4-phenyl piperidine 6 with s-BuLi and diamine (S,S)-2 (Et2O, Ð
78 ¡C, 1 h) was followed by trapping with a range of electrophiles, giving cis-disubstituted piperidines 21-
24 as single diastereomers in good er, but moderate yield (Scheme 6). Trapping with dimethyl sulfate gave 
(R,R)-21 in 22% yield and 91:9 er (with 50% recovered starting material), phenyl isocyanate gave amide 
(S,R)-22 in 25% yield and 89:11 er (with 49% recovered starting material) and PhMe2SiCl gave (R,R)-23 
in 43% yield and 92:8 er. Use of the enantiomeric ligand (R,R)-2, trapping with Me3SiCl, gave (S,S)-24 in 
48% yield and 87:13 er.12a In comparison, lithiation with s-BuLi and (Ð)-sparteine or the (+)-sparteine 
surrogate 1 was much less successful. Use of (Ð)-sparteine resulted in a much poorer yield, with (S,S)-24 
being isolated in only 6% yield and 78:22 er.12a Conversely, the use of the (+)-sparteine surrogate 1 gave 
(R,R)-24 in an excellent 89% yield but poorer 70:30 er. The cis-diastereomers are formed by equatorial 
lithiation of a conformation with an equatorial phenyl group and retentive trapping.22 The moderate yields 
with the Alexakis diamines can be explained by stalling in the lithiation step, as observed by in situ IR 
spectroscopy (see SI for full details).  
 
Scheme 6. Lithiation-trapping of N-Boc-4-phenyl piperidine 6. alithiation time 3 h; busing (R,R)-2; 
clithiation time 6 h; dusing 1   
 
Finally, we re-visited the asymmetric lithiation-trapping of N-Boc-4-chloro piperidine 7.12d Treatment of 
N-Boc-4-chloro piperidine 7 with 2.2 eq. of s-BuLi and diamine (R,R)-2 (Ð78 ¡C, 1 h) followed by trapping 
with phenyl isocyanate gave amide (S,R)-25 in 86% yield and 74:26 er (Scheme 7). In comparison, use of 
pseudephedrine derived (R,R)-3 gave (S,R)-25 in 81% yield and a poorer 62:38 er. In contrast, use of the 
more established diamines, (Ð)-sparteine and (+)-sparteine surrogate 1, resulted in near-racemic 25 being 
isolated (56:44 er and 46:54 er respectively).12d  
 
Scheme 7. Lithiation-trapping of N-Boc-4-phenyl piperidine 7 
 
In conclusion, we describe the first spectroscopic and synthetic investigation of the asymmetric lithiation-
trapping of six-membered N-Boc-activated nitrogen heterocycles using the Alexakis diamines 2 and 3 as 
ligands. Indeed, this is the first report of pseudoephedrine-derived 3 being used for the asymmetric lithiation 
of any N-Boc heterocycle. In comparison with the established diamines, (Ð)-sparteine and (+)-sparteine 
surrogate 1, these readily available ligands give superior results in the lithiation of N-Boc piperazines, 
followed by trapping with benzophenone and the lithiation-trapping of N-Boc-4-chloro piperidine 7. 
Furthermore, we have demonstrated the asymmetric synthesis of single diastereomers of 2,4-cis-
disubstituted piperidines from N-Boc-4-phenyl piperidine 6. The use of in situ IR spectroscopy has provided 
information on lithiation times and revealed the subtle effect of the lithiation of 6, 13 and 18 stalling at 
~50% in the presence of diamine (S,S)-2. Additionally, this technique revealed the fact that the lithiation of 
differentially protected N-Boc piperazines using s-BuLi and (R,R)-3 occur at similar rates, unlike the 
analogous reactions using the sparteine class of ligands.  
EXPERIMENTAL 
For full details of the synthesis of starting materials and diamines as well as in situ IR experiments and 
NMR and CSP-HPLC data, see the supporting information.  
 
General procedure A: Lithiation-trapping of N-Boc piperazines and N-Boc-4-phenyl piperidine 6. s-
BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of N-Boc heterocycle 
(1.0−1.95 mmol, 1.0 eq.) and diamine (1.3 eq.) in Et2O (3.5-10.5 mL) at −78 ¡C under Ar. The resulting 
solution was stirred at −78 ¡C for 1 h. Then, the electrophile (2.0 eq.) was added dropwise, as a solution in 
Et2O (1 mL) if necessary. The reaction mixture was allowed to warm slowly to rt overnight. Then, saturated 
NH4Cl(aq) (10 mL), 20% NaOH(aq) (10 mL), and Et2O (10 mL) were added, and the two layers were separated. 
The aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), 
filtered, and evaporated under reduced pressure to give the crude product. 
 
General procedure B: Lithiation-trapping of N-Boc-4-chloro piperidine 7. s-BuLi (1.3 M solution in 
hexanes, 2.2 eq.) was added dropwise to a stirred solution of N-Boc-4-chloro piperidine 7 (0.75−1.09 mmol, 
1.0 eq.) and diamine (2.2 eq.) in Et2O (5.5-8.0 mL) at −78 ¡C under Ar. The resulting solution was stirred 
at −78 ¡C for 1 h. Then, phenyl isocyanate (2.2 eq.) was added dropwise. The reaction mixture was allowed 
to warm slowly to rt overnight. Then, saturated NH4Cl(aq) (10 mL), and Et2O (10 mL) were added, and the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic 
layers were dried (MgSO4), filtered, and evaporated under reduced pressure to give the crude product.  
 
(8aS)-7-Benzyl-1,1-diphenyl-hexahydro-1H-[1,3]oxazolo[3,4-a]-piperazin-3-one (S)-11: Using general 
procedure A, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 1.3 eq.), (S,S)-2 (606 mg, 1.95 
mmol, 1.3 eq.), and N-Boc-NÕ-benzyl piperazine 8 (415 mg, 1.5 mmol, 1.0 eq.) in Et2O (10.5 mL) and a 
solution of benzophenone (547 mg, 3.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude product which 
contained an 87:13 mixture of (S)-11 and alkene 12 (by 1H NMR spectroscopy). Purification by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave oxazolidinone (S)-11 (345 mg, 60%, 
86:14 er by CSP-HPLC) as a white solid, mp 146Ð149 ¡C; RF (7:3 petrol-EtOAc) 0.2; 
1H NMR (400 MHz, 
CDCl3) δ 7.53Ð7.50 (m, 2H, Ph), 7.40Ð7.21 (m, 13H, Ph), 4.54 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.80 (ddd, 
J = 13.0, 3.5, 1.5 Hz, 1H, NCH), 3.50 (d, J = 13.0 Hz, 1H, CH2Ph), 3.31 (d, J = 13.0 Hz, 1H, CH2Ph), 3.09 
(ddd, J = 13.0, 12.0, 3.5 Hz, 1H, NCH), 2.70Ð2.66 (m, 1H, NCH), 2.55 (ddd, J = 11.0, 3.5, 1.5 Hz, 1H, 
NCH), 1.93 (td, J = 12.0, 3.5 Hz, 1H, NCH), 1.57 (t, J = 11.0 Hz, 1H, NCH); 13C NMR (100.6 MHz, CDCl3) 
δ 156.5 (C=O), 142.7 (ipso-Ph), 139.1 (ipso-Ph), 137.6 (ipso-Ph), 129.1 (Ph), 128.8 (Ph), 128.7 (Ph), 128.6 
(Ph), 128.5 (Ph), 128.1 (Ph), 127.6 (Ph), 126.2 (Ph), 126.0 (Ph), 85.3 (Ph2CO), 62.9 (NCH2), 61.1 (NCH), 
55.7 (NCH2), 50.7 (NCH2), 41.5 (NCH2); HRMS (ESI) m/z calcd for C25H25N2O2 (M + H)
+ 385.1911, found 
385.1899 (Ð3.1 ppm error); [α]D Ð157.7 (c 1.0 in CHCl3) (lit.
16a [α]D Ð114.9 (c 1.0 in CHCl3) for (S)-11 of 
75:25 er); CSP-HPLC: Chiralcel OD (90:10 hexane:i-PrOH, 1.0 mL minÐ1) (S)-11 12.9 min, (R)-11 17.4 
min. Spectroscopic data consistent with those reported in the literature.16a  
Diagnostic signals for alkene 12: 1H NMR (400 MHz, CDCl3) (67:33 mixture of rotamers) δ 6.03 (d, J = 
6.5 Hz, 0.33H, CH=CHNBoc), 5.88 (d, J = 6.5 Hz, 0.67H, CH=CHNBoc), 5.49 (d, J = 6.5 Hz, 0.33H, 
CH=CHNBoc), 5.38 (d, J = 6.5 Hz, 0.67H, CH=CHNBoc), 3.94 (s, 2H, CH2Ph). 
 
(8aS)-7-Methyl-1,1-diphenyl-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-3-one (S)-16: Using general 
procedure A, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 1.3 eq.), (S,S)-2 (606 mg, 1.95 
mmol, 1.3 eq.) and N-Boc-NÕ-methyl piperazine 13 (300 mg, 1.5 mmol, 1.0 eq.) in Et2O (10.5 mL) and a 
solution of benzophenone (547 mg, 3.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude product which 
contained a 98:2 mixture of (S)-16 and alkene 17 (by 1H NMR spectroscopy). Purification by flash column 
chromatography on silica with 99:1 to 96:4 CH2Cl2-MeOH as eluent gave oxazolidinone (S)-16 (221 mg, 
48%, 92:8 er by CSP-HPLC) as a white solid, mp 96Ð98 ¡C; RF (19:1 CH2Cl2-MeOH) 0.4; 
1H NMR (400 
MHz, CDCl3) 7.52Ð7.47 (m, 2H, Ph), 7.37Ð7.23 (m, 8H, Ph), 4.50 (dd, J = 11.0, 3.5 Hz, 1H, NCH), 3.83 
(ddd, J = 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.12 (ddd, J = 13.0, 12.0, 3.5 Hz, 1H, NCH), 2.68Ð2.64 (m, 1H, 
NCH), 2.43 (ddd, J = 12.0, 3.5, 1.0 Hz, 1H, NCH), 2.18 (s, 3H, NMe), 1.93 (td, J = 12.0, 3.5 Hz, 1H, NCH), 
1.43 (t, J = 11.0 Hz, 1H, NCH); 13C NMR (100.6 MHz, CDCl3) δ 158.8 (C=O), 142.2 (ipso-Ph), 138.6 
(ipso-Ph), 128.5 (Ph), 128.3 (Ph), 128.2 (Ph), 127.8 (Ph), 125.8 (Ph), 125.6 (Ph), 85.1 (Ph2CO), 60.9 (NCH), 
56.9 (NCH2), 53.2 (NCH2), 46.3 (NMe), 41.5 (NCH2); HRMS (ESI) m/z calcd for C19H21N2O2 (M+H)
+ 
309.1598, found 309.1599 (+0.1 ppm error); [α]D Ð221.7 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel AD 
(90:10 hexane:i-PrOH, 1.0 mL minÐ1) (S)-16 11.7 min, (R)-16 17.4 min. Spectroscopic data consistent with 
those reported in the literature.18c 
Diagnostic signals for alkene 17: 1H NMR (400 MHz, CDCl3) (67:33 mixture of rotamers) δ 6.04 (d, J = 
6.5 Hz, 0.33H, CH=CHNBoc), 5.88 (d, J = 6.5 Hz, 0.67H, CH=CHNBoc), 5.28 (d, J = 6.5 Hz, 0.33H, 
CH=CHNBoc), 5.18 (d, J = 6.5 Hz, 0.67H, CH=CHNBoc), 2.57, (s, 2H, NMe), 2.56, (s, 1H, NMe). 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.), (+)-1 (252 
mg, 1.3 mmol, 1.3 eq.) and N-Boc-NÕ-methyl piperazine 13 (200 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) 
and a solution of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude product which 
contained a 44:56 mixture of (S)-16 and alkene 17 (by 1H NMR spectroscopy). Purification by flash column 
chromatography on silica with 99:1 to 96:4 CH2Cl2-MeOH as eluent gave oxazolidinone (S)-16 (120 mg, 
39%, 85:15 er by CSP-HPLC) as a white solid, CSP-HPLC: Chiralcel AD (90:10 hexane:i-PrOH, 1.0 mL 
minÐ1) (S)-16 12.2 min, (R)-16 18.0 min. 
 
(8aR)-7-Methyl-1,1-diphenyl-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-3-one (R)-16: Using general 
procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.), (R,R)-3 (450 mg, 1.3 
mmol, 1.3 eq.) and N-Boc-NÕ-methyl piperazine 13 (200 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) and a 
solution of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude product. Purification 
by flash column chromatography on silica with 99:1 to 96:4 CH2Cl2-MeOH as eluent gave oxazolidinone 
(R)-16 (170 mg, 55%, 92:8 er by CSP-HPLC) as a white solid, [α]D +235.0 (c 1.0 in CHCl3); CSP-HPLC: 
Chiralcel AD (90:10 hexane:i-PrOH, 1.0 mL minÐ1) (S)-16 11.9 min, (R)-16 15.5 min. 
 
Using general procedure A, s-BuLi (1.5 mL of a 1.3 M solution in hexanes, 1.95 mmol, 1.3 eq.), (Ð)-
sparteine (448 μL, 1.95 mmol, 1.3 eq.) and N-Boc-NÕ-methyl piperazine 13 (300 mg, 1.5 mmol, 1.0 eq.) in 
Et2O (10.5 mL) and a solution of benzophenone (547 mg, 3.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude 
product which contained a 78:22 mixture of (R)-16 and alkene 17 (by 1H NMR spectroscopy). Purification 
by flash column chromatography on silica with 99:1 to 96:4 CH2Cl2-MeOH as eluent gave oxazolidinone 
(R)-16 (210 mg, 45%, 88:12 er by CSP-HPLC) as a white solid, CSP-HPLC: Chiralcel AD (90:10 hexane:i-
PrOH, 1.0 mL minÐ1) (S)-16 12.2 min, (R)-16 16.7 min. 
 
(8aS)-7-tert-Butyl-1,1-diphenyl-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-3-one (S)-19: Using 
general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.), (S,S)-2 (403 mg, 
1.3 mmol, 1.3 eq.) and N-Boc-NÕ-tert-butyl piperazine 18 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) and 
a solution of benzophenone (364 mg, 2.0 mmol, 2.0 eq.) in Et2O (1 mL) gave the crude product. Purification 
by flash column chromatography on silica with 99:1 to 97:3 CH2Cl2-MeOH as eluent gave oxazolidinone 
(S)-19 (125 mg, 36%, 85:15 er by CSP-HPLC) as a white solid, mp 193Ð195 ¡C; RF (99:1 CH2Cl2-MeOH) 
0.2; 1H NMR (400 MHz, CDCl3) δ 7.53Ð7.50 (m, 2H, Ph), 7.39Ð7.24 (m, 8H, Ph), 4.43 (dd, J = 11.0, 3.5 
Hz, 1H, NCH), 3.85 (ddd, J = 13.0, 3.5, 1.0 Hz, 1H, NCH), 3.08 (ddd, J = 13.0, 12.0, 3.5 Hz, 1H, NCH), 
2.92Ð2.88 (m, 1H, NCH), 2.62 (ddd, J = 12.0, 3.5, 1.0 Hz, 1H, NCH), 2.06 (td, J = 12.0, 3.5 Hz, 1H, NCH), 
1.51 (t, J = 11.0 Hz, 1H, NCH), 0.93 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 156.1 (C=O), 142.4 
(ipso-Ph), 138.8 (ipso-Ph), 128.5 (Ph), 128.4 (Ph), 128.2 (Ph), 127.8 (Ph), 126.0 (Ph), 125.7 (Ph), 85.4 
(Ph2CO), 61.9 (NCH), 54.3 (CMe3), 48.8 (NCH2), 44.8 (NCH2), 42.6 (NCH2), 26.0 (CMe3); HRMS (ESI) 
m/z calcd for C23H27N2O2 (M + H)
+ 351.2067, found 351.2062 (Ð1.4 ppm error); [α]D Ð144.6 (c 1.0 in CHCl3) 
(lit.16a [α]D +184.1 (c 1.0 in CHCl3) for (R)-19 of 90:10 er); CSP-HPLC: Chiralcel OD-H (90:10 hexane:i-
PrOH, 0.5 mL minÐ1) (S)-19 13.4 min, (R)-19 17.3 min. Spectroscopic data consistent with those reported 
in the literature.16a  
 
1-tert-Butyl 2-methyl (2S)-4-tert-butylpiperazine-1,2-dicarboxylate (S)-20: Using general procedure A, 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.), (S,S)-2 (403 mg, 1.3 mmol, 1.3 eq.) and 
N-Boc-NÕ-tert-butyl piperazine 18 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) and methyl chloroformate 
(155 μL, 2.0 mmol, 2.0 eq.) gave the crude product. Purification by flash column chromatography on silica 
with 7:3 petrol-EtOAc as eluent gave ester (S)-20 (103 mg, 34%, 88:12 er by CSP-HPLC) as a pale yellow 
oil, RF (7:3 petrol-EtOAc) 0.4; 
1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 4.70 (br s, 0.5H, 
NCH), 4.53 (br s, 0.5H, NCH), 3.83 (br d, J = 12.5 Hz, 0.5H, NCH), 3.75Ð3.73 (m, 0.5H, NCH), 3.73 (s, 
1.5H, OMe), 3.72 (s, 1.5H, OMe), 3.52Ð3.45 (m, 1H, NCH), 3.13 (td, J = 12.5, 3.5 Hz, 0.5H, NCH), 3.03 
(td, J = 12.5, 3.5 Hz, 0.5H, NCH), 2.92 (br d, J = 11.0 Hz, 0.5H, NCH), 2.84 (br d, J = 11.0 Hz, 0.5H, 
NCH), 2.28Ð2.23 (m, 1H, NCH), 2.11 (td, J = 11.0, 3.5 Hz, 1H, NCH), 1.46 (s, 4.5H, OCMe3), 1.42 (s, 
4.5H, OCMe3), 0.96 (s, 9H, NCMe3); 
13C NMR (100.6 MHz, CDCl3) (mixture of rotamers) δ 171.6 
(CO2Me), 171.3 (CO2Me), 155.8 (NC=O), 155.4 (NC=O), 80.0 (OCMe3), 56.3 (NCH), 55.0 (NCH), 53.3 
(NCMe3), 51.9 (OMe), 47.6 (NCH2), 45.2 (NCH2), 42.9 (NCH2), 42.0 (NCH2), 28.3 (CMe3), 25.8 (CMe3); 
HRMS (ESI) m/z calcd for C15H29N2O4 (M + H)
+ 301.2122, found 301.2122 (0.0 ppm error); [α]D Ð21.2 (c 
1.0 in CHCl3); (lit.
16a [α]D +22.2 (c 1.0 in CHCl3) for (R)-20 of 89:11 er); CSP-HPLC: Chiralcel AD (99:1 
hexane:i-PrOH, 1.0 mL minÐ1) (R)-20 13.4 min, (S)-20 19.5 min. Spectroscopic data consistent with those 
reported in the literature.16a 
 
1-tert-Butyl 2-methyl (2R)-4-tert-butylpiperazine-1,2-dicarboxylate (R)-20: Using general procedure A, 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.), (R,R)-3 (404 mg, 1.3 mmol, 1.3 eq.) 
and N-Boc-NÕ-tert-butyl piperazine 18 (242 mg, 1.0 mmol, 1.0 eq.) in Et2O (7 mL) and methyl 
chloroformate (155 μL, 2.0 mmol, 2.0 eq.) gave the crude product. Purification by flash column 
chromatography on silica with 7:3 petrol-EtOAc as eluent gave ester (R)-20 (206 mg, 69%, 81:19 er by 
CSP-HPLC) as a pale yellow oil, CSP-HPLC: Chiralcel AD (99:1 hexane:i-PrOH, 1.0 mL minÐ1) (R)-20 
13.9min, (S)-20 23.7 min. 
 
tert-Butyl (2R,4R)-2-methyl-4-phenylpiperidine-1-carboxylate (R,R)-21: Using general procedure A, s-
BuLi (1.15 mL of a 1.3 M solution in hexanes, 1.5 mmol, 1.3 eq.), (S,S)-2 (465 mg, 1.5 mmol, 1.3 eq.) and 
N-Boc-4-phenyl piperidine 6 (300 mg, 1.15 mmol, 1.0 eq.) in Et2O (3.8 mL) and Me2SO4 (210 μL, 2.3 
mmol, 2.0 eq.) gave the crude product containing a single diastereomer of (R,R)-21. Purification by flash 
column chromatography on silica with 97:3 hexane-EtOAc as eluent gave piperidine (R,R)-21 (70 mg, 22%, 
91:9 er by CSP-HPLC) as a colourless oil, RF (95:5 hexane-EtOAc) 0.2; IR (CHCl3) 2973, 2932, 1692 
(C=O), 1478, 1453, 1413, 1365, 1250, 1171, 1142, 759, 700 cmÐ1; 1H NMR (400 MHz, CDCl3) δ 7.35Ð
7.28 (m, 2H, Ph), 7.25Ð7.17 (m, 3H, Ph), 4.02Ð3.90 (m, 1H, NCH), 3.81 (ddd, J = 14.0, 7.5, 3.0 Hz, 1H, 
NCH), 3.25 (ddd, J = 14.0, 10.0, 6.5 Hz, 1H, NCH), 2.81Ð2-71 (m, 1H, CHPh), 2.22Ð2.10 (m, 1H, CH), 
1.91 (dddd, J = 13.5, 6.5, 3.0, 1.5 Hz, 1H, CH), 1.68Ð1.56 (m, 2H, CH), 1.49 (s, 9H, CMe3), 1.20 (d, J = 
6.5 Hz, 3H, Me); 13C NMR (100.6 MHz, CDCl3) δ 155.8 (C=O), 146.4 (ipso-Ph), 128.7 (Ph), 127.1 (Ph), 
126.5 (Ph), 79.2 (CMe3), 49.9 (NCH), 37.7 (CHPh), 37.4 (NCH2), 36.9 (CH2), 31.0 (CH2), 28.3 (CMe3), 
19.5 (Me); HRMS (ESI) m/z calcd for C17H25NO2 (M + H)
+ 276.1958, found 276.1953 (Ð1.8 ppm error); 
[α]D Ð68.8 (c 0.55 in CHCl3) (lit.,
23 [α]D Ð72.1 (c 0.6 in CHCl3) for (R,R)-21); CSP-HPLC: Chiralcel OD 
(99:1 hexane-i-PrOH, 0.5 mL minÐ1) (S,S)-21 15.9 min, (R,R)-21 17.3 min and starting material 6 (152 mg, 
50%) as a colourless oil. Spectroscopic data consistent with those reported in the literature.23 
 
tert-Butyl (2S,4R)-4-phenyl-2-(phenylcarbamoyl)piperidine-1-carboxylate (S,R)-22: Using general 
procedure A, s-BuLi (1.15 mL of a 1.3 M solution in hexanes, 1.5 mmol, 1.3 eq.), (S,S)-2 (465 mg, 1.5 
mmol, 1.3 eq.) and N-Boc-4-phenyl piperidine 6 (300 mg, 1.15 mmol, 1.0 eq.) in Et2O (3.8 mL) and phenyl 
isocyanate (250 μL, 2.3 mmol, 2.0 eq.) gave the crude product containing a single diastereomer of (S,R)-
22. Purification by flash column chromatography on silica with 97:3 CH2Cl2-Et2O as eluent gave piperidine 
(S,R)-22 (110 mg, 25%, 89:11 er by CSP-HPLC) as a white solid, mp 222Ð224 ¡C (lit.,22b 225Ð226 ¡C); RF 
(97:3 CH2Cl2-Et2O) 0.2; IR (CHCl3) 2982, 1692 (C=O), 1600, 1524, 1442, 1155, 905, 730, 650 cm
Ð1; 1H 
NMR (400 MHz, CDCl3) δ 8.17 (br s, 1H, NH), 7.53 (dd, J = 8.5, 1.0 Hz, 2H, Ph), 7.36Ð7.29 (m, 4H, Ph), 
7.28Ð7.20 (m, 3H, Ph), 7.11 (tt, J = 7.5, 1.0 Hz, 1H, Ph), 4.38 (dd, J = 8.5, 8.5 Hz, 1H, NCH), 3.71Ð3.55 
(m, 2H, NCH), 2.78 (dddd, J = 10.5, 10.5, 6.5, 6.5 Hz, 1H, CHPh), 2.31Ð2.19 (m, 2H, CH), 2.14 (dddd, J 
= 13.5, 6.5, 6.5, 6.5 Hz, 1H, CH), 1.75 (dddd, J = 13.5, 10.5, 6.0, 6.0 Hz, 1H, CH), 1.47 (s, 9H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) δ 170.1 (C=O), 156.7 (C=O), 145.1 (ipso-Ph), 137.9 (ipso-Ph), 129.0 (Ph), 
128.6 (Ph), 126.8 (Ph), 126.5 (Ph), 124.1 (Ph), 119.5 (Ph), 81.5 (CMe3), 58.5 (NCH), 41.7 (NCH2), 37.8 
(CH), 31.7 (CH2), 30.9 (CH2), 28.3 (CMe3); HRMS (ESI) m/z calcd for C23H29N2O3 (M + H)
+ 381.2173, 
found 381.2162 (Ð2.9 ppm error).; [α]D Ð48.7 (c 1.0 in CHCl3) CSP-HPLC: Chiralcel OD (90:10 hexane-i-
PrOH, 1.0 mL minÐ1) (R,S)-22 11.7 min, (S,R)-22 17.0 min and starting material 6 (148 mg, 49%) as a 
colourless oil. Spectroscopic data consistent with those reported in the literature.22b  
 
tert-Butyl (2R,4R)-2-[dimethyl(phenyl)silyl]-4-phenylpiperidine-1-carboxylate (R,R)-23: Using 
general procedure A, s-BuLi (1.15 mL of a 1.3 M solution in hexanes, 1.5 mmol, 1.3 eq.), (S,S)-2 (465 mg, 
1.5 mmol, 1.3 eq.) and N-Boc-4-phenyl piperidine 6 (300 mg, 1.15 mmol, 1.0 eq.) in Et2O (3.8 mL) for 3 h 
at Ð78 ¡C and PhMe2SiCl (386 μL, 2.3 mmol, 2.0 eq.) gave the crude product containing a single 
diastereomer of (R,R)-23. Purification by flash column chromatography on silica with 96:4 petrol-EtOAc 
as eluent gave piperidine (R,R)-23 (170 mg, 43%, 92:8 er by CSP-HPLC) as a white solid, mp 144Ð145 ¡C; 
RF (96:4 petrol-EtOAc) 0.3; IR (CHCl3) 3020, 1685 (C=O), 1425, 1218, 929, 782, 736, 669 cm
Ð1; 1H NMR 
(400 MHz, CDCl3) δ 7.63Ð7.56 (m, 2H, Ph), 7.38Ð7.28 (m, 5H, Ph), 7.25Ð7.16 (m, 3H, Ph), 4.11 (br s, 1H, 
NCH), 3.09Ð2.91 (br m, 1H, NCH), 2.79Ð2.60 (br m, 1H, NCH), 2.67 (dddd, J = 12.0, 12.0, 4.0, 4.0 Hz, 
1H, CHPh), 1.88Ð1.77 (m, 2H, CH), 1.73Ð1.54 (m, 2H, CH), 1.47 (s, 9H, CMe3), 0.48 (s, 3H, SiMe), 0.44 
(s, 3H, SiMe); 13C NMR (100.6 MHz, CDCl3) δ 155.6 (C=O), 146.4 (ipso-Ph), 142.1 (ipso-Ph), 134.3 (Ph), 
128.7 (Ph), 128.5 (Ph), 127.7 (Ph), 127.1 (Ph), 126.5 (Ph), 79.3 (CMe3), 50.1 (NCH), 47.0 (NCH2), 44.4 
(CHPh), 33.4 (CH2), 28.1 (CMe3), Ð2.7 (SiMe), Ð3.3 (SiMe); HRMS (ESI) m/z calcd for C24H34NO2Si (M 
+ H)+ 396.2353, found 396.2348 (Ð1.3 ppm error), [α]D Ð44.0 (c 1.0 in CHCl3) CSP-HPLC: Chiralcel OD 
(99.9:0.1 hexane-i-PrOH, 0.5 mL minÐ1) (S,S)-23 12.0 min, (R,R)-23 13.2 min.  
 
tert-Butyl (2R,4R)-4-Phenyl-2-(trimethylsilyl)piperidine-1-carboxylate (R,R)-24: Using general 
procedure A, s-BuLi (1.25 mL of 1.18 M solution in cyclohexane, 1.47 mmol, 1.3 eq.), (+)-1 (286 mg, 1.47 
mmol, 1.3 eq.) and N-Boc-4-phenyl piperidine 6 (289 mg, 1.11 mmol, 1.0 eq.) in Et2O (3.8 mL) for 6 h at 
Ð78 ¡C and Me3SiCl (352 µL, 2.77 mmol, 2.5 eq.) gave the crude product containing a single diastereomer 
of (R,R)-24. Purification by flash column chromatography on silica with 96:4 petrol-Et2O as eluent gave 
piperidine (R,R)-24 (329 mg, 89%, 70:30 er by CSP-GC) as a colourless oil, [α]D Ð1.4 (c 1.0 in CHCl3) 
(lit.,12a [α]D +4.6 (c 1.1, CHCl3) for (S,S)-24 87:13 er) Spectroscopic data consistent with that previously 
reported.12a 
CSP-GC: β-cyclodextrin-permethylated 120 fused silica capillary column 30 m × 0.25 mm i.d. [20% 
permethylated β-cyclodextrin in SPB-35 poly (35% diphenyl/65% dimethyl)siloxane, hydrogen carrier at 
14 psi], retention times 34.0 min and 34.6 min (isothermal at 140 ¡C). 
 
tert-Butyl (1S,5R)-1-(phenylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (S,R)-25: Using 
general procedure B, s-BuLi (1.85 mL of a 1.3 M solution in hexanes, 2.4 mmol, 2.2 eq.), (R,R)-2 (745 mg, 
2.4 mmol, 2.2 eq.) and N-Boc-4-chloro piperidine 7 (240 mg, 1.09 mmol, 1.0 eq.) in Et2O (8 mL) and 
phenyl isocyanate (261 μL, 2.4 mmol, 2.2 eq.) gave the crude product. Purification by flash column 
chromatography on silica with 98:2 CH2Cl2-Et2O as eluent gave amide (S,R)-25 (282 mg, 86%, 74:26 er by 
CSP-HPLC) as a pale yellow solid, mp 102Ð103 ¡C; RF (98:2 CH2Cl2-Et2O) 0.2; IR (CDCl3) 3408 (NH), 
2979, 1689 (C=O), 1682 (C=O), 1529, 1444, 1368, 1164, 908, 732 cmÐ1; 1H NMR (400 MHz, CDCl3) δ 
8.32 (br s, 1H, NH), 7.49 (d, J = 8.0 Hz, 2H, Ph), 7.30 (t, J = 8.0 Hz, 2H, Ph), 7.07 (d, J = 8.0 Hz, 1H, Ph), 
3.75 (ddd, J = 11.5, 9.0, 6.5 Hz, 1H, NCH), 3.66 (ddd, J = 11.5, 8.5, 5.5 Hz, 1H, NCH), 2.24 (ddt, J = 13.0, 
9.0, 6.5 Hz, 1H, CH), 2.17-2.12 (m, 1H,CH), 2.07 (dd, J = 9.0, 5.0 Hz, 1H, CH), 1.94 (dddd, J = 13.0, 8.5, 
6.5, 1.5 Hz, 1H, CH), 1.42 (s, 9H, CMe3), 1.02 (t, J = 5.0 Hz, 1H, CH); 
13C NMR (100.6 MHz, CDCl3) δ 
168.6 (PhNCO) 156.9 (NCO2CMe3), 137.8 (ipso-Ph), 128.9 (Ph), 123.9 (Ph), 119.3 (Ph), 81.2 (CMe3), 51.3 
(NCH2), 50.6 (NC), 31.1 (CH), 28.1 (CMe3), 26.4 (CH2), 24.8 (CH2); HRMS m/z calcd for C17H22N2NaO3 
(M + Na)+ 325.1523, found 325.1523 (0.0 ppm error); CSP-HPLC: Chiracel OD (90:10 hexane-i-PrOH, 
1.0 mL minÐ1) (R,S)-25 7.4 min, (S,R)-25 14.5 min. Spectroscopic data consistent with those reported in the 
literature.12d 
 
Using general procedure B, s-BuLi (1.27 mL of a 1.3 M solution in hexanes, 1.65 mmol, 2.2 eq.), (R,R)-3 
(572 mg, 1.65 mmol, 2.2 eq.) and N-Boc-4-chloro piperidine 7 (164 mg, 0.75 mmol, 1.0 eq.) in Et2O (5 
mL) and phenyl isocyanate (179 μL, 1.65 mmol, 2.2 eq.) gave the crude product. Purification by flash 
column chromatography on silica with 98:2 CH2Cl2-Et2O as eluent gave amide (S,R)-25 (182 mg, 81%, 
62:38 er by CSP-HPLC) as a pale yellow solid, CSP-HPLC: Chiracel OD (90:10 hexane-i-PrOH, 1.0 mL 
minÐ1) (R,S)-25 7.4 min, (S,R)-25 14.8 min. 
 
Using general procedure B, s-BuLi (1.69 mL of a 1.3 M solution in hexanes, 2.2 mmol, 2.2 eq.), (Ð)-
sparteine (506 μL, 2.2 mmol, 2.2 eq.) and N-Boc-4-chloro piperidine 7 (219 mg, 1.0 mmol, 1.0 eq.) in Et2O 
(8 mL) and phenyl isocyanate (239 μL, 2.2 mmol, 2.2 eq.) gave the crude product. Purification by flash 
column chromatography on silica with 98:2 CH2Cl2-Et2O as eluent gave amide (S,R)-25 (283 mg, 94%, 
56:44 er by CSP-HPLC) as a pale yellow solid, CSP-HPLC: Chiracel OD (90:10 hexane-i-PrOH, 1.0 mL 
minÐ1) (R,S)-25 7.2 min, (S,R)-25 13.6 min. 
 
tert-Butyl (1R,5S)-1-(phenylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (R,S)-25: Using 
general procedure B, s-BuLi (1.51 mL of a 1.3 M solution in hexanes, 1.96 mmol, 2.2 eq.), (+)-1 (381 mg, 
1.96 mmol, 2.2 eq.) and N-Boc-4-chloro piperidine 7 (194 mg, 0.89 mmol, 1.0 eq.) in Et2O (5.5 mL) and 
phenyl isocyanate (179 μL, 1.65 mmol, 2.2 eq.) gave the crude product. Purification by flash column 
chromatography on silica with 98:2 CH2Cl2-Et2O as eluent gave amide (R,S)-25 (212 mg, 79%, 54:46 er by 
CSP-HPLC) as a pale yellow solid, CSP-HPLC: Chiracel OD (90:10 hexane-i-PrOH, 1.0 mL minÐ1) (R,S)-
25 7.4 min, (S,R)-25 14.8 min. 
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